HONG KONG – China bioprocessing technology firm Hangzhou Just Biotherapeutics Ltd. (HJB) and clinical-stage biotech Mabspace Biosciences Co. Ltd. have entered a merger agreement to establish a biotherapeutics maker, Transcenta Holding Ltd., with the aim of shortening the time from target to biologics license applications, and setting up a next-generation GMP facility that supports the development and commercialization of molecules both in-house and from its partners.